Allard J, Lawthom C, Henley W, et al. - The investigator sought to reinforce the research evidence on eslicarbazepine acetate (ESL), a new anti‐epileptic drug (AED), by contrasting the response of individuals with intellectual disability (ID) to those from the general population who do not have ID. Data were obtained for 93 people (36 ID and 57 ‘no ID’). Tolerance and efficacy for ID and ‘no ID’ people in the dataset were comparable. Improvements in seizure and retention rates were slightly lower than those found in other European datasets, but results support evidence for the use of ESL in the ID population.